Clinical Trial Update: Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lenvatinib as adjuvant therapy to prevent recurrence after curative surgery in high-risk hepatocellular carcinoma patients; cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Hepatocellular Carcinoma (HCC), Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation | Phase 2 | Status: RECRUITING